Institute of Clinical Chemistry and Laboratory Medicine, General Hospital Steyr, Steyr, Austria.
Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
Nephrol Dial Transplant. 2018 Nov 1;33(11):1984-1991. doi: 10.1093/ndt/gfy025.
Beta-trace protein (BTP) is a low-molecular-weight glycoprotein, which may serve as an endogenous biomarker of kidney function and cardiovascular risk.
We examined cardiovascular and all-cause mortality according to BTP concentrations in 2962 individuals referred for coronary angiography from the Ludwigshafen Risk and Cardiovascular Health study and in 907 patients with Type 2 diabetes mellitus undergoing haemodialysis from the German Diabetes and Dialysis (4D) study.
Haemodialysis patients had considerably higher median (interquartile range) BTP concentrations [6.00 (4.49-7.96) mg/L] and experienced a 4-fold increased mortality rate compared with coronary angiography patients [BTP concentration: 0.55 (0.44-0.67) mg/L]. After adjustment for age, sex, cardiovascular risk factors and creatinine, 4D patients in the highest quartile (>7.96 mg/L) had a 1.6-fold increased rate of all-cause mortality [hazard ratio (HR) 1.62, 95% confidence interval (CI) 1.19-2.20] compared with the lowest quartile (<4.49 mg/L) (P = 0.002) In patients undergoing coronary angiography, the adjusted HRs (95% CI) for all-cause and cardiovascular mortality were 1.23 (1.0-1.51) and 1.27 (0.99-1.63) in the highest (>0.67 mg/L) compared with the lowest (<0.44 mg/L) quartile (P = 0.043 and 0.062). In both cohorts, the BTP/creatinine ratio was a stronger predictor of all-cause and cardiovascular mortality compared with BTP.
BTP was associated with all-cause mortality independently of renal function in haemodialysis patients. The BTP/creatinine ratio was more predictive for all-cause and cardiovascular mortality in haemodialysis patients and individuals referred for angiography compared with BTP as single marker.
β-痕迹蛋白(BTP)是一种低分子量糖蛋白,可作为肾功能和心血管风险的内源性生物标志物。
我们根据来自 Ludwigshafen 风险和心血管健康研究的 2962 名接受冠状动脉造影的患者和来自德国糖尿病和透析(4D)研究的 907 名接受血液透析的 2 型糖尿病患者的 BTP 浓度,检查了心血管和全因死亡率。
血液透析患者的 BTP 浓度中位数(四分位距)明显较高[6.00(4.49-7.96)mg/L],与冠状动脉造影患者相比,死亡率增加了 4 倍[BTP 浓度:0.55(0.44-0.67)mg/L]。在调整年龄、性别、心血管危险因素和肌酐后,4D 患者中 BTP 浓度最高(>7.96mg/L)的全因死亡率增加了 1.6 倍[风险比(HR)1.62,95%置信区间(CI)1.19-2.20]与最低四分位数(<4.49mg/L)相比(P=0.002)。在接受冠状动脉造影的患者中,BTP 浓度最高(>0.67mg/L)与最低(<0.44mg/L)四分位数相比,全因和心血管死亡率的调整 HR(95%CI)分别为 1.23(1.0-1.51)和 1.27(0.99-1.63)(P=0.043 和 0.062)。在两个队列中,BTP/肌酐比值比 BTP 更能预测全因和心血管死亡率。
在血液透析患者中,BTP 与全因死亡率独立于肾功能相关。与 BTP 作为单一标志物相比,BTP/肌酐比值在血液透析患者和接受血管造影的个体中对全因和心血管死亡率的预测更准确。